Bicycle Therapeutics PLC (NASDAQ:BCYC)
| 25.39 BATS BZX Real-Time Price As of 11:36am ET |  -0.61 / -2.35%Today’s Change | 12.08 Today|||52-Week Range 33.49 | -14.22% Year-to-Date |
Institutional investors purchased a net $2.3 million shares of BCYC during the quarter ended March 2019. This may signal that the smart money is gaining interest in this company as the 86.06% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
| Other institutional | 66.84% |
| Mutual fund holders | 19.22% |
| Individual stakeholders | -- |
Largest Quarterly Institutional
Transactions
Latest Institutional Activity
| 3/31/2023 | JEFFERIES LLC Bought 1.9 Million shares of Bicycle Therapeutics PLC |
| 3/31/2023 | MORGAN STANLEY & CO. LLC Bought 786.9 Thousand shares of Bicycle Therapeutics PLC |
| 3/31/2023 | ARMISTICE CAPITAL LLC Bought 736.0 Thousand shares of Bicycle Therapeutics PLC |
Top 10 Owners of Bicycle Therapeutics PLC
| Stockholder | Stake | Shares owned | Total value ($) | Shares bought / sold | Total change |
|---|---|---|---|---|---|
| Deep Track Capital LP | 9.39% | 2,819,045 | 55,704,329 | 0 | 0.00% |
| Ridgeback Capital Management LLC | 7.54% | 2,264,801 | 44,752,468 | +100,000 | +4.62% |
| Jefferies LLC | 6.49% | 1,948,000 | 38,492,480 | +1,948,000 | -- |
| Paradigm BioCapital Advisors LP | 6.05% | 1,816,781 | 35,899,593 | +583,501 | +47.31% |
| Morgan Stanley & Co. LLC | 5.00% | 1,502,398 | 29,687,384 | +786,859 | +109.97% |
| Janus Henderson Investors US LLC | 4.91% | 1,474,378 | 29,133,709 | -29,069 | -1.93% |
| Tybourne Capital Management (HK) ... | 4.69% | 1,408,831 | 27,838,501 | +503,109 | +55.55% |
| Candriam Belgium SA | 4.34% | 1,303,211 | 25,751,449 | +128,000 | +10.89% |
| Polar Capital LLP | 3.36% | 1,009,500 | 19,947,720 | +259,500 | +34.60% |
| Sio Capital Management LLC | 3.22% | 967,347 | 19,114,777 | +283,922 | +41.54% |
Top 10 Mutual Funds Holding Bicycle Therapeutics PLC
| Mutual fund | Stake | Shares owned | Total value ($) | Shares bought / sold | Total change |
|---|---|---|---|---|---|
| Polar Capital Funds Plc - Biotech... | 2.50% | 750,000 | 14,820,000 | -250,000 | -25.00% |
| Candriam Equities L - Oncology Im... | 2.17% | 652,934 | 12,901,976 | +30,000 | +4.82% |
| Belfius Equities - Cure | 2.17% | 652,934 | 12,901,976 | 0 | 0.00% |
| Candriam Equities L - Biotechnolo... | 1.79% | 537,295 | 10,616,949 | -20,000 | -3.59% |
| Janus Henderson Global Life Scien... | 1.74% | 521,492 | 10,304,682 | -6,711 | -1.27% |
| Janus Henderson Capital Funds Plc... | 1.40% | 419,722 | 8,293,707 | -5,859 | -1.38% |
| BNP Paribas Funds - Health Care I... | 1.15% | 345,713 | 6,831,289 | 0 | 0.00% |
| Fidelity Select Port. - Biotechno... | 0.96% | 287,147 | 5,674,025 | 0 | 0.00% |
| AXA Framlington Biotech Fund | 0.96% | 286,644 | 5,664,085 | +5,929 | +2.11% |
| T Rowe Price Health Sciences Fund | 0.79% | 237,347 | 4,689,977 | -17,323 | -6.80% |